133 related articles for article (PubMed ID: 18308802)
1. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy.
Potvin S; Kouassi E; Lipp O; Bouchard RH; Roy MA; Demers MF; Gendron A; Astarita G; Piomelli D; Stip E
J Psychopharmacol; 2008 May; 22(3):262-9. PubMed ID: 18308802
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.
Igue R; Potvin S; Bah R; Stip E; Bouchard RH; Lipp O; Gendron A; Kouassi E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1695-8. PubMed ID: 21627977
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.
Potvin S; Stip E; Lipp O; Elie R; Mancini-Marië A; Demers MF; Roy MA; Bouchard RH; Gendron A
Curr Med Res Opin; 2006 Jul; 22(7):1277-85. PubMed ID: 16834826
[TBL] [Abstract][Full Text] [Related]
4. Attentional improvement following quetiapine fumarate treatment in schizophrenia.
Sax KW; Strakowski SM; Keck PE
Schizophr Res; 1998 Oct; 33(3):151-5. PubMed ID: 9789907
[TBL] [Abstract][Full Text] [Related]
5. Quetiapine: treatment for substance abuse and drug of abuse.
Hanley MJ; Kenna GA
Am J Health Syst Pharm; 2008 Apr; 65(7):611-8. PubMed ID: 18359967
[TBL] [Abstract][Full Text] [Related]
6. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine.
Vesely C; Küfferle B; Brücke T; Kasper S
Int Clin Psychopharmacol; 2000 Jan; 15(1):57-60. PubMed ID: 10836289
[TBL] [Abstract][Full Text] [Related]
7. Intranasal quetiapine abuse.
Pierre JM; Shnayder I; Wirshing DA; Wirshing WC
Am J Psychiatry; 2004 Sep; 161(9):1718. PubMed ID: 15337673
[No Abstract] [Full Text] [Related]
8. Quetiapine-associated depression in a patient with schizophrenia.
Mergui J; Jaworowski S; Lerner V
Clin Neuropharmacol; 2005; 28(3):133-5. PubMed ID: 15965312
[TBL] [Abstract][Full Text] [Related]
9. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
Westheide J; Cvetanovska G; Albrecht C; Bliesener N; Cooper-Mahkorn D; Creutz C; Hornung WP; Klingmüller D; Lemke MR; Maier W; Schubert M; Sträter B; Kühn KU
J Sex Med; 2008 Dec; 5(12):2816-26. PubMed ID: 18466271
[TBL] [Abstract][Full Text] [Related]
10. Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms.
Ebdrup BH; Skimminge A; Rasmussen H; Aggernaes B; Oranje B; Lublin H; Baaré W; Glenthøj B
Int J Neuropsychopharmacol; 2011 Feb; 14(1):69-82. PubMed ID: 20701823
[TBL] [Abstract][Full Text] [Related]
11. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study.
Skryabin VY; Vinnikova MA; Ezhkova EV; Titkov MS; Bulatova RA
J Addict Dis; 2021; 39(4):513-525. PubMed ID: 33832406
[TBL] [Abstract][Full Text] [Related]
13. Anandamide dysfunction in prodromal and established psychosis.
Leweke FM
Curr Pharm Des; 2012; 18(32):5188-93. PubMed ID: 22716147
[TBL] [Abstract][Full Text] [Related]
14. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Byerly MJ; Nakonezny PA; Rush AJ
Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.
Nikisch G; Baumann P; Oneda B; Kiessling B; Weisser H; Mathé AA; Yoshitake T; Kehr J; Wiedemann G; Eap CB
J Psychopharmacol; 2011 Jul; 25(7):896-907. PubMed ID: 21148022
[TBL] [Abstract][Full Text] [Related]
16. Prolactin elevation with quetiapine.
Alexiadis M; Whitehorn D; Woodley H; Kopala L
Am J Psychiatry; 2002 Sep; 159(9):1608-9. PubMed ID: 12202292
[No Abstract] [Full Text] [Related]
17. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
18. The effect of quetiapine on aggression and hostility in patients with schizophrenia.
Arango C; Bernardo M
Hum Psychopharmacol; 2005 Jun; 20(4):237-41. PubMed ID: 15830402
[TBL] [Abstract][Full Text] [Related]
19. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
[TBL] [Abstract][Full Text] [Related]
20. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
Nakajima M; Terao T; Iwata N; Nakamura J
Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
